Product Information
ATOVAQUONE 750 MG/5 ML SUSP is a generic product labeled by PAI Holdings LLC, priced at $0.7668 per ML under NDC 00121095608. Its NADAC has been published 66 times since Jul 2, 2025.
FDA first approved this application on Oct 25, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
750 mg/5mL
Manufacturer
PAI Holdings LLCNDC
00121095608
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ATOVAQUONEApproval Type
Generic (ANDA)
FDA Application
ANDA214272FDA Approved
10/25/2021
TE Code
AB
On Market Since
4/4/2025
Pharmacological Classes
Price Statistics
The NADAC for ATOVAQUONE 750 MG/5 ML SUSP has been published 66 times since Jul 2, 2025, and over the history we have for it it has declined 10.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7668 per ML |
|---|---|
| All-time high | $0.8766 (Oct 15, 2025) |
| All-time low | $0.6842 (Jul 22, 2026) |
| 52-week high | $0.8766 |
| 52-week low | $0.6842 |
| Median price | $0.7455 |
| Average price | $0.7655 |
| Largest weekly change | +10.5% (Aug 19, 2026) |
| Weeks tracked | 66 |
| Tracking since | Jul 2, 2025 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 3% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
PAI Holdings LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Atovaquone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antimalarial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ATOVAQUONE 750 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for ATOVAQUONE 750 MG/5 ML SUSP, manufactured by PAI Holdings LLC, is $0.7668 per ML (NDC 00121095608), effective Sep 30, 2026.
How has the price of ATOVAQUONE 750 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for ATOVAQUONE 750 MG/5 ML SUSP has declined 10.4%. It has been tracked across 66 weekly CMS publications since Jul 2, 2025.
What are the highest and lowest recorded NADAC prices for ATOVAQUONE 750 MG/5 ML SUSP?
Since Jul 2, 2025, the NADAC for ATOVAQUONE 750 MG/5 ML SUSP has ranged from a low of $0.6842 (Jul 22, 2026) to a high of $0.8766 (Oct 15, 2025), with a median of $0.7455 per ML.
Are there cheaper alternatives to ATOVAQUONE 750 MG/5 ML SUSP?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ATOVAQUONE 750 MG/5 ML SUSPENSION CUP, is $0.7418 per ML — about 3% below ATOVAQUONE 750 MG/5 ML SUSP.
Who manufactures ATOVAQUONE 750 MG/5 ML SUSP?
ATOVAQUONE 750 MG/5 ML SUSP (NDC 00121095608) is labeled by PAI Holdings LLC, and CMS classifies it as a generic product.